<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26796">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983215</url>
  </required_header>
  <id_info>
    <org_study_id>2013H0045</org_study_id>
    <nct_id>NCT01983215</nct_id>
  </id_info>
  <brief_title>Effects of Prevena Therapy on Obese and or Diabetic Patients With Surgical Groin Sites</brief_title>
  <official_title>EFFECTS OF PREVENA THERAPY ON REDUCTION OF GROIN SURGICAL SITE INFECTIONS IN OBESE PATIENTS UNDERGOING VASCULAR SURGERY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Jean E. Starr, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effects of Prevena therapy on decreasing groin
      surgical site infections in patients who are obese and /or diabetic having vascular surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are obese and/or diabetic may have poor surgical healing and infection rates
      higher. The PREVENA therapy will be used to evaluate possible reduction of infection rates
      in this patient population
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of patients with infections</measure>
    <time_frame>30 day post surgical procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>reduction of 30 day surgical site infection by evaluating infection rates in obese, diabetic patients who were randomized to Prevena Vac vs. standard of care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>infection rates</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>reduction of 1 year graft infection in prosthetic grafts and reduction of secondary hospitalizations for infection.Patients will be followed through 1 year to measure results of infection rates and secondary hospitalization related to infection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>negative pressure dressing vs. standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm study- randomized Prevena vac or standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena vac</intervention_name>
    <arm_group_label>negative pressure dressing vs. standard of care</arm_group_label>
    <other_name>randomized 1:1 negative pressure dressing vs. standard of care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects over 18 years old

          -  obese (BMI &gt; 30) and or diabetic

        Exclusion Criteria:

          -  current infected surgical field, hemodialysis, immunosuppressive therapy, allergy to
             adhesive, sensitivity to silver
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean E Starr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State Division of Vascular Diseases and Surgery</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Ohio State University</investigator_affiliation>
    <investigator_full_name>Dr. Jean E. Starr, MD</investigator_full_name>
    <investigator_title>Vascular surgeon</investigator_title>
  </responsible_party>
  <keyword>groin incisions</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
